Neratinib

XTX Topco Ltd reduced its stake in Puma Biotechnology by 45.7% in Q3. Several institutional investors adjusted their holdings in Puma Biotechnology in Q2. Puma Biotechnology's stock opened at $2.75 on Friday, with a market cap of $134.99M. The company reported $0.41 EPS for Q3, surpassing estimates. StockNews.com downgraded Puma Biotechnology from 'strong-buy' to 'buy'. Puma Biotechnology focuses on cancer care products, including NERLYNX.

The biotech industry is growing rapidly due to advancements in genomic research, personalized medicine, and innovative platforms, with key stocks like HRMY, TRDA, and PBYI leading the charge. The global biotechnology market is projected to reach $4.61 trillion by 2034, driven by increased investment, favorable regulations, and high demand for novel therapies. TRDA specializes in EEV therapeutics for neuromuscular diseases, HRMY focuses on rare and neurological diseases, and PBYI develops cancer treatments, all showing strong financials and growth potential.

Puma Biotechnology granted a 7,500-share restricted stock unit award to a new non-executive employee on Dec 2, 2024, under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with vesting conditions tied to continued employment.

Puma Biotechnology (NASDAQ: PBYI) approved a 7,500-share restricted stock unit award for a new non-executive employee under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with one-third vesting on December 1, 2025, and one-sixth every six months thereafter, contingent on continued employment, complying with Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology initiates ALISCA™-Breast1 Phase II trial of alisertib combined with endocrine therapy for HR+, HER2-negative recurrent or metastatic breast cancer patients previously treated with CDK 4/6 inhibitors. The trial aims to determine the optimal alisertib dose and evaluate efficacy endpoints within biomarker subgroups, with initial data expected in 2025.

Puma Biotechnology reported Q3 2024 revenue of $80.5 million, up from $51.6 million in Q3 2023, driven by NERLYNX sales and royalty revenue from China. The company discussed ongoing clinical trials, including Phase 2 studies of alisertib, and provided financial forecasts for Q4 and fiscal year 2024.

Puma Biotechnology reported Q3 2024 revenue of $80.5M, including $56.1M from NERLYNX® and $24.4M in royalties, with net income of $20.3M ($0.41 per share). The company updated its 2024 guidance to $187-190M in net product revenue and $15-17M in net income.

Puma Biotechnology's Q3 2024 earnings show a significant increase in net income and total revenue, driven by robust NERLYNX sales and higher royalty revenue. Key metrics include a 9% rise in product revenue to $56.1 million, net income of $20.3 million ($0.41 per share), and total revenue of $80.5 million. The company holds $97 million in cash and is advancing its alisertib development for cancer treatment.